CG Oncology, Inc. (CGON)
(Real Time Quote from BATS)
$30.51 USD
-0.01 (-0.03%)
Updated Jun 27, 2024 03:06 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for CG Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 0 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 56 | 35 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -55 | -35 | 0 | 0 | 0 |
Non-Operating Income | 7 | 0 | NA | NA | NA |
Interest Expense | 0 | 0 | NA | NA | NA |
Pretax Income | -49 | -35 | NA | NA | NA |
Income Taxes | 0 | 0 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -49 | -35 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -49 | -35 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -58 | -35 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | -3 | 0 | NA | NA | NA |
Income After Depreciation & Amortization | -55 | -35 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.33 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -15.65 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -15.65 | NA | NA | NA | NA |
Fiscal Year end for CG Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.53 | NA | NA | NA | 0.19 |
Cost Of Goods | 0.00 | NA | NA | NA | 0.00 |
Gross Profit | 0.53 | NA | NA | NA | 0.19 |
SG&A, R&D, and Dept/Amort Expenses | 23.00 | 0.00 | 0.00 | 0.00 | 9.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.47 | 0.00 | 0.00 | 0.00 | -9.72 |
Non-Operating Income | 5.54 | NA | NA | NA | 1.05 |
Interest Expense | 0.00 | NA | NA | NA | 0.00 |
Pretax Income | -16.93 | NA | NA | NA | -8.67 |
Income Taxes | 0.00 | NA | NA | NA | 0.00 |
Minority Interest | 0.00 | NA | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | NA | NA | 0.00 |
Other Income/Charges | 0.00 | NA | NA | NA | 0.00 |
Income From Cont. Operations | -16.93 | NA | NA | NA | -8.67 |
Extras & Discontinued Operations | 0.00 | NA | NA | NA | 0.00 |
Net Income (GAAP) | -16.93 | NA | NA | NA | -8.67 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 47.07 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.36 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.36 | NA | NA | NA | NA |